Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and corporate update on August 4, 2020. A conference call will follow at 5:00 p.m. ET where participants can join by calling 1-800-353-6461 in the U.S. or 1-334-323-0501 internationally.

Corcept focuses on developing drugs that target cortisol effects for severe metabolic, oncologic, and psychiatric disorders. Its first product, Korlym®, is approved for Cushing’s syndrome. The company holds significant intellectual property related to its cortisol modulators.

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
To participate, dial 1-800-353-6461 from the United States or 1-334-323-0501 internationally approximately ten minutes before the start of the call. The passcode will be 6800706.

A replay will be available through August 18, 2020 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 6800706.

About Corcept Therapeutics Incorporated

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds, that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

CONTACT:
Christopher S. James, MD
Director, Investor Relations
Corcept Therapeutics
650-684-8725
cjames@corcept.com
www.corcept.com

 

FAQ

When will Corcept Therapeutics release its second quarter financial results?

Corcept Therapeutics will release its second quarter financial results on August 4, 2020.

What time is the conference call for Corcept's financial results?

The conference call for Corcept's financial results will be held at 5:00 p.m. Eastern Time on August 4, 2020.

How can I participate in Corcept's conference call?

To participate in Corcept's conference call, dial 1-800-353-6461 from the U.S. or 1-334-323-0501 internationally approximately ten minutes before the start.

What is Korlym® by Corcept Therapeutics?

Korlym® is the first drug approved by the FDA for patients with Cushing’s syndrome, developed by Corcept Therapeutics.